NYSE:PFE

Pfizer (PFE) Stock Forecast, Price & News

$38.02

+1.01 (+2.73%)

(As of 05/31/2023 ET)

Compare

Today's Range: $36.87
▼
$38.22
50-Day Range: $36.48
▼
$41.79
52-Week Range: $36.17
▼
$54.93

Volume: 43.78 million shs
Average Volume: 28.46 million shs
Market Capitalization: $214.63 billion

P/E Ratio: 7.48
Dividend Yield: 4.31%
Price Target: $47.33

Pfizer MarketRank™ Forecast

Analyst Rating: Hold
2.31 Rating Score
Upside/Downside: 24.5% Upside
$47.33 Price Target
Short Interest: Healthy
0.81% of Shares Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.04
Upright™ Environmental Score
News Sentiment: 0.43
Based on 42 Articles This Week
Insider Trading: Acquiring Shares
$5.08 M Bought Last Quarter
Proj. Earnings Growth: -0.30%
From $3.35 to $3.34 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.03 out of 5 stars

Medical Sector

5th out of 1,006 stocks

Pharmaceutical Preparations Industry

2nd out of 492 stocks

3.2

Analyst's Opinion

Consensus Rating
Pfizer has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 4 buy ratings, 9 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $47.33, Pfizer has a forecasted upside of 24.5% from its current price of $38.02.
Amount of Analyst Coverage
Pfizer has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
0.81% of the outstanding shares of Pfizer have been sold short.
Short Interest Ratio / Days to Cover
Pfizer has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pfizer has recently increased by 4.67%, indicating that investor sentiment is decreasing.

5.0

Dividend Strength

Dividend Leadership
Pfizer is a leading dividend payer. It pays a dividend yield of 4.36%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Pfizer has been increasing its dividend for 12 years.
Dividend Coverage
The dividend payout ratio of Pfizer is 32.28%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Pfizer will have a dividend payout ratio of 49.10% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Pfizer has received a 71.87% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Covid-19 vaccines", "Pneumococcal vaccines", and "Apixaban" products. See details.
Environmental Sustainability
The Environmental Impact score for Pfizer is -2.04.

2.5

News and Social Media Coverage

News Sentiment
Pfizer has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 42 news articles for Pfizer this week, compared to 23 articles on an average week.
Search Interest
Only 205 people have searched for PFE on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.
MarketBeat Follows
89 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is an increase of 27% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pfizer insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,076,999.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.05% of the stock of Pfizer is held by insiders.
Percentage Held by Institutions
67.62% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Pfizer are expected to decrease by -0.30% in the coming year, from $3.35 to $3.34 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pfizer is 7.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.89.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pfizer is 7.48, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 146.37.
Price to Earnings Growth Ratio
Pfizer has a PEG Ratio of 1.25. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Pfizer has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pfizer (NYSE:PFE) Stock

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.

Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Stock News Headlines

May 31, 2023 | marketbeat.com

The How and Why of Investing in Biotech Stocks (PFE)

One fascinating sector to invest in is the biotech sector which includes companies involved in the research and development of therapeutics and vaccines

May 30, 2023 | marketbeat.com

3 Stocks Worth Buying at 52-Week Lows (PFE)

Here are three stocks that are trading near their 52-week lows and may be primed for a short-term rally for opportunistic investors

June 1, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.

May 27, 2023 | marketbeat.com

MarketBeat Week in Review – 5/22 - 5/26 (PFE)

The debt ceiling standoff and inflation continue to fight for investors’ attention as we head into what is historically a quieter period for the markets

May 25, 2023 | marketbeat.com

Pfizer Has the Prescription for Higher Share Prices

Pfizer's 4% yield is more attractive than ever after positive results from a study and an upgrade from Cantor Fitzgerald.

May 23, 2023 | marketbeat.com

Doximity is an Overlooked Medical Ecosystem AI Play (PFE)

Doximity Inc. (NASDAQ: DOCS) is a digital professional social network platform for medical practitioners. It’s a medical community networking platform like

May 19, 2023 | marketbeat.com

Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?

Despite worries about FTC scrutiny, Pfizer remains optimistic about its planned Seagen acquisition, issuing $31 billion in bonds to finance the deal.

May 18, 2023 | marketbeat.com

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (PFE)

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

June 1, 2023 | Legacy Research (Affiliate) (Ad)

The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty

A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.

May 16, 2023 | marketbeat.com

The Turnaround for Weight Watchers is Taking Shape (PFE)

Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares

May 10, 2023 | marketbeat.com

5 Best Healthcare Sector ETFs (PFE)

What do you need to know about investing in healthcare ETFs? Learn more about both healthcare and ETFs with MarketBeat.

May 8, 2023 | marketbeat.com

ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results (PFE)

Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug

May 31, 2023 | stockhouse.com

U.S. FDA Approves ABRYSVO(TM), Pfizer's Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults

May 31, 2023 | benzinga.com

U.S. FDA Approves ABRYSVO™, Pfizer's Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults

May 31, 2023 | msn.com

Why Pfizer Stock Is Perking Up Today

May 31, 2023 | reuters.com

US FDA approves Pfizer's RSV vaccine

May 31, 2023 | msn.com

Pfizer’s RSV Shot Wins US Approval Following GSK’s to Market

May 31, 2023 | finance.yahoo.com

Does Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?

May 31, 2023 | finance.yahoo.com

Pfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study

May 31, 2023 | markets.businessinsider.com

Pfizer Says Pivotal Phase 3 BASIS Clinical Trial Of Marstacimab Met Primary Endpoints

May 30, 2023 | msn.com

Pfizer Unusual Options Activity For May 30

May 30, 2023 | finance.yahoo.com

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

May 30, 2023 | finance.yahoo.com

Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial

May 30, 2023 | finance.yahoo.com

Pfizer's hemophilia therapy reduces bleeding in late-stage study

May 30, 2023 | finance.yahoo.com

Pfizer's Approach To Hemophilia Is 'Certainty Differentiated' — Here's Why Shares Fell

May 30, 2023 | seekingalpha.com

Pfizer: The New Oral Weight Loss Therapy Could Be A Game Changer

May 29, 2023 | seekingalpha.com

Pfizer: Not Quite Dead Money Walking

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Company Calendar

Ex-Dividend for 3/3 Dividend: 1/26/2023
Dividend Payable: 3/03/2023
Last Earnings: 5/02/2023
Ex-Dividend for 6/9 Dividend: 5/11/2023
Today: 6/01/2023
Dividend Payable: 6/09/2023
Next Earnings (Estimated): 7/27/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:PFE
CUSIP: 71708110
CIK: 78003
Web: www.pfizer.com
Phone: (212) 733-2323
Fax: 302-655-5049
Employees: 83,000
Year Founded: 1849

Price Target and Rating

Average Stock Price Forecast: $47.33
High Stock Price Forecast: $75.00
Low Stock Price Forecast: $38.00
Forecasted Upside/Downside: +24.5%
Consensus Rating: Hold
Rating Score (0-4): 2.31
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): $5.08
Trailing P/E Ratio: 7.48
Forward P/E Ratio: 11.35
P/E Growth: 1.23
Net Income: $31.37 billion
Net Margins: 31.25%
Pretax Margin: 34.37%
Return on Equity: 37.53%
Return on Assets: 18.08%

Debt

Debt-to-Equity Ratio: 0.31
Current Ratio: 1.37
Quick Ratio: 1.11

Sales & Book Value

Annual Sales: $100.33 billion
Price / Sales: 2.14
Cash Flow: $7.82 per share
Price / Cash Flow: 4.86
Book Value: $17.93 per share
Price / Book: 2.12

Miscellaneous

Outstanding Shares: 5,645,310,000
Free Float: 5,642,484,000
Market Cap: $214.63 billion
Optionable: Optionable
Beta: 0.63

Social Links

Key Executives

Albert Bourla
Chairman & Chief Executive Officer

David M. Denton
Chief Financial Officer & Executive Vice President

Annaliesa Anderson
SVP, Head-Vaccine Research & Development

Mikael Dolsten
Co-Chief Scientific Officer & President-Research

Jeff Settleman
Co-Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PFE Stock - Frequently Asked Questions

Should I buy or sell Pfizer stock right now?: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PFE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.
View PFE analyst ratings or view top-rated stocks.
What is Pfizer's stock price forecast for 2023?: 13 brokers have issued 12 month price objectives for Pfizer's shares. Their PFE share price forecasts range from $38.00 to $75.00. On average, they expect the company's share price to reach $47.33 in the next year. This suggests a possible upside of 24.5% from the stock's current price.
View analysts price targets for PFE or view top-rated stocks among Wall Street analysts.
How have PFE shares performed in 2023?: Pfizer's stock was trading at $51.24 at the beginning of 2023. Since then, PFE stock has decreased by 25.8% and is now trading at $38.02.
View the best growth stocks for 2023 here.
When is Pfizer's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our PFE earnings forecast.
How were Pfizer's earnings last quarter?: Pfizer Inc. (NYSE:PFE) issued its quarterly earnings results on Tuesday, May, 2nd. The biopharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.00 by $0.23. The biopharmaceutical company earned $18.28 billion during the quarter, compared to analyst estimates of $16.49 billion. Pfizer had a trailing twelve-month return on equity of 37.53% and a net margin of 31.25%. The company's quarterly revenue was down 28.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.62 EPS.
Read the conference call transcript.
How often does Pfizer pay dividends? What is the dividend yield for Pfizer?: Pfizer declared a quarterly dividend on Wednesday, April 26th. Shareholders of record on Friday, May 12th will be given a dividend of $0.41 per share on Friday, June 9th. This represents a $1.64 dividend on an annualized basis and a yield of 4.31%. The ex-dividend date of this dividend is Thursday, May 11th.
Read our dividend analysis for PFE.
What ETFs hold Pfizer's stock?: ETFs with the largest weight of Pfizer (NYSE:PFE) stock in their portfolio include First Trust Nasdaq Pharmaceuticals ETF (FTXH), Horizon Kinetics Medical ETF (MEDX), Invesco Dynamic Pharmaceuticals ETF (PJP), VanEck Pharmaceutical ETF (PPH), iShares Core High Dividend ETF (HDV), Pacer US Cash Cows Growth ETF (BUL), IQ Healthy Hearts ETF (HART) and iShares U.S. Healthcare ETF (IYH).
Is Pfizer a good dividend stock?: Pfizer (NYSE:PFE) pays an annual dividend of $1.64 per share and currently has a dividend yield of 4.36%. PFE has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 32.28%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PFE will have a dividend payout ratio of 49.10% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PFE.
What guidance has Pfizer issued on next quarter's earnings?: Pfizer updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share guidance of $3.25-$3.45 for the period, compared to the consensus EPS estimate of $3.36. The company issued revenue guidance of $67.00 billion-$71.00 billion, compared to the consensus revenue estimate of $68.67 billion.

What is Albert Bourla's approval rating as Pfizer's CEO?: 358 employees have rated Pfizer Chief Executive Officer Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among the company's employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Pfizer own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS), Exxon Mobil (XOM), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).
What is Pfizer's stock symbol?: Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."
Who are Pfizer's major shareholders?: Pfizer's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.89%), State Street Corp (4.99%), Wellington Management Group LLP (3.88%), Geode Capital Management LLC (1.95%), Charles Schwab Investment Management Inc. (1.49%) and Bank of New York Mellon Corp (0.92%). Insiders that own company stock include Alexander R Mackenzie, Douglas M Lankler, Jennifer B Damico, John D Young, Pfizer Inc, Ronald E Blaylock, Scott Gottlieb and William R Carapezzi Jr.
View institutional ownership trends.
How do I buy shares of Pfizer?: Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pfizer's stock price today?: One share of PFE stock can currently be purchased for approximately $38.02.
How much money does Pfizer make?: Pfizer (NYSE:PFE) has a market capitalization of $214.63 billion and generates $100.33 billion in revenue each year. The biopharmaceutical company earns $31.37 billion in net income (profit) each year or $5.08 on an earnings per share basis.
How many employees does Pfizer have?: The company employs 83,000 workers across the globe.
Does Pfizer have any subsidiaries?: The following companies are subsidiares of Pfizer: AH Robins LLC, AHP Manufacturing B.V., Agouron Pharmaceuticals LLC, Alpharma Pharmaceuticals LLC, American Food Industries LLC, Amplyx Pharmaceuticals, Amplyx Pharmaceuticals Inc., Anacor Pharmaceuticals, Anacor Pharmaceuticals Inc., Angiosyn, Arena, Array BioPharma, Array BioPharma Inc., BIND Therapeutics Inc., Bamboo Therapeutics, Bamboo Therapeutics Inc., Baxter International - Marketed Vaccines, BioRexis, Bioren, Blue Whale Re Ltd., C.P. Pharmaceuticals International C.V., CICL Corporation, COC I Corporation, Catapult Genetics, Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Coley Pharmaceutical Group Inc., Covx, Cyanamid de Argentina S.A., Cyanamid de Colombia S.A., Distribuidora Mercantil Centro Americana S.A., Encysive Pharmaceuticals, Encysive Pharmaceuticals Inc., Esperion Therapeutics, Excaliard Pharmaceuticals, Farminova Produtos Farmaceuticos de Inovacao Lda., FoldRx Pharmaceuticals LLC, Foldrx Pharmaceuticals, Fort Dodge Manufatura Ltda., G. D. Searle & Co. Limited, G. D. Searle International Capital LLC, GI Europe Inc., GI Japan Inc., GenTrac Inc., Genetics Institute LLC, Hospira, Hospira Adelaide Pty Ltd, Hospira Australia Pty Ltd, Hospira Benelux BVBA, Hospira Holdings (S.A.) Pty Ltd, Hospira Inc., Hospira Limited, Hospira Philippines Inc., Hospira Pte. Ltd., Hospira Puerto Rico LLC, Hospira UK Limited, Hospira Worldwide LLC, Hospira Zagreb d.o.o., ICAgen, Idun Pharmaceuticals, InnoPharma, InnoPharma Inc., International Affiliated Corporation LLC, John Wyeth & Brother Limited, King Pharmaceuticals Holdings LLC, King Pharmaceuticals LLC, King Pharmaceuticals Research and Development LLC, Laboratoires Pfizer S.A., Laboratorios Pfizer Ltda., Laboratorios Wyeth LLC, Laboratorios Wyeth S.A., Laboratórios Pfizer Lda., MTG Divestitures LLC, Mayne Pharma IP Holdings (Euro) Pty Ltd, Medivation, Medivation Field Solutions LLC, Medivation LLC, Medivation Neurology LLC, Medivation Prostate Therapeutics LLC, Medivation Services LLC, Medivation Technologies LLC, Monarch Pharmaceuticals LLC, Neusentis Limited, NextWave Pharmaceuticals, P-D Co. LLC, PAH USA IN8 LLC, PBG Puerto Rico LLC, PF Argentum Acquisition ULC, PF Consumer Healthcare Holdings LLC, PF Consumer Healthcare Holdings US Inc., PF Czech Republic Holdings B.V., PF Finland Holdings B.V., PF OFG Ireland 2 B.V., PF OFG South Korea 1 B.V., PF OFG South Korea 2 B.V., PF PR Holdings C.V., PF PRISM C.V., PF PRISM Holdings B.V., PF PRISM IMB B.V., PFE Wyeth-Ayerst (Asia) LLC, PFIZER (VIETNAM) LIMITED COMPANY, PHIVCO Corp., PHIVCO Holdco S.à r.l., PIMB OFG Spain Holding S.L., PRISM Holdings B.V., PT. Pfizer Indonesia, Parke Davis & Company LLC, Parke Davis Limited, Parkedale Pharmaceuticals Inc., Peak Enterprises LLC, Pfizer, Pfizer (China) Research and Development Co. Ltd., Pfizer (Malaysia) Sdn Bhd, Pfizer (Perth) Pty Ltd, Pfizer (Thailand) Limited, Pfizer (Wuhan) Research and Development Co. Ltd., Pfizer AB, Pfizer AG, Pfizer AS, Pfizer Afrique de L'Ouest, Pfizer Anti-Infectives AB, Pfizer ApS, Pfizer Asia Manufacturing Pte. Ltd., Pfizer Australia Holdings B.V., Pfizer Australia Holdings Pty Limited, Pfizer Australia Investments Pty Ltd, Pfizer Australia Pty Ltd, Pfizer B.V., Pfizer Biopharma Egypt LLC, Pfizer Biopharmaceuticals Egypt LLC, Pfizer Bolivia S.A., Pfizer Canada ULC / Pfizer Canada SRI, Pfizer Chile S.A., Pfizer Cia. Ltda., Pfizer Colombia Spinco I LLC, Pfizer Consumer Healthcare, Pfizer Cork Limited, Pfizer Corporation Austria Gesellschaft m.b.H., Pfizer Corporation Hong Kong Limited, Pfizer Corporation S. de R.L., Pfizer Croatia d.o.o., Pfizer Deutschland GmbH, Pfizer Development B.V., Pfizer Development LLC, Pfizer Development LP, Pfizer Development Services (UK) Limited, Pfizer East India B.V., Pfizer Eastern Investments B.V., Pfizer Europe MA EEIG, Pfizer Export B.V., Pfizer Export Company, Pfizer Finance Share Service (Dalian) Co. Ltd., Pfizer France International Investments, Pfizer Free Zone Panama S. de R.L., Pfizer Global Holdings B.V., Pfizer Global Supply Japan Inc., Pfizer Global Trading, Pfizer Gulf FZ-LLC, Pfizer H.C.P. Corporation, Pfizer Health AB, Pfizer Health Solutions Inc., Pfizer Healthcare India Private Limited, Pfizer Healthcare Ireland, Pfizer Hellas A.E., Pfizer Himalaya Holdings Coöperatief U.A., Pfizer Holding France, Pfizer Holdings Corporation, Pfizer Holdings International Corporation, Pfizer Holdings International Luxembourg (PHIL) Sarl, Pfizer Inc., Pfizer Innovations AB, Pfizer Innovations LLC, Pfizer International LLC, Pfizer International Operations, Pfizer Investment Capital Unlimited Company, Pfizer Investment Co. Ltd., Pfizer Ireland PFE Holding 1 LLC, Pfizer Ireland PFE Holding 2 LLC, Pfizer Ireland Pharmaceuticals, Pfizer Ireland Ventures Unlimited Company, Pfizer Italia S.r.l., Pfizer Japan Inc., Pfizer Laboratories (Pty) Limited, Pfizer Laboratories Limited, Pfizer Leasing Ireland Limited, Pfizer Leasing UK Limited, Pfizer Limited, Pfizer Luxco Holdings SARL, Pfizer Luxembourg Global Holdings S.à r.l., Pfizer Luxembourg SARL, Pfizer MAP Holding Inc., Pfizer Manufacturing Austria G.m.b.H., Pfizer Manufacturing Belgium N.V., Pfizer Manufacturing Deutschland GmbH, Pfizer Manufacturing Deutschland Grundbesitz GmbH & Co. KG, Pfizer Manufacturing Holdings LLC, Pfizer Manufacturing Ireland Unlimited Company, Pfizer Manufacturing LLC, Pfizer Manufacturing Services, Pfizer Medicamentos Genericos e Participacoes Ltda., Pfizer Mexico Holding B.V., Pfizer New Zealand Limited, Pfizer North America Services LLC, Pfizer OTC B.V., Pfizer Overseas LLC, Pfizer Oy, Pfizer PFE AsiaPac Holding B.V., Pfizer PFE CIA. Ltda., Pfizer PFE Eastern Investments B.V., Pfizer PFE Global Holdings B.V., Pfizer PFE Pharmaceuticals Israel Holding LLC, Pfizer PFE Pharmaceuticals Israel Ltd., Pfizer PFE Service Company Holding B.V., Pfizer PFE Spain B.V., Pfizer PFE UK Holding 4 LP, Pfizer PFE İlaçları Anonim Şirketi, Pfizer Pakistan Limited, Pfizer Pharm Algerie, Pfizer Pharma GmbH, Pfizer Pharma PFE GmbH, Pfizer Pharmaceutical (Wuxi) Co. Ltd., Pfizer Pharmaceutical Trading Limited Liability Company (a/k/a Pfizer Kft. or Pfizer LLC), Pfizer Pharmaceuticals Global B.V., Pfizer Pharmaceuticals Israel Ltd., Pfizer Pharmaceuticals Korea Limited, Pfizer Pharmaceuticals Science and Technology Co. Ltd., Pfizer Pigments Inc., Pfizer Polska Sp. z.o.o., Pfizer Private Limited, Pfizer Production LLC, Pfizer Products Inc., Pfizer Products India Private Limited, Pfizer R&D Holding B.V., Pfizer R&D Japan G.K., Pfizer R&D UK Limited, Pfizer Research (NC) Inc., Pfizer Romania SRL, Pfizer S.A., Pfizer S.A., Pfizer S.A. de C.V., Pfizer S.A.S., Pfizer S.G.P.S. Lda., Pfizer S.L., Pfizer S.R.L., Pfizer SA (Belgium), Pfizer SRB d.o.o., Pfizer Saudi Limited, Pfizer Service Company BVBA, Pfizer Service Company Ireland Unlimited Company, Pfizer Shared Services Unlimited Company, Pfizer Shareholdings Intermediate SARL, Pfizer Singapore Holding Pte. Ltd., Pfizer Specialties Limited, Pfizer Trading Polska sp.z.o.o., Pfizer Transactions LLC, Pfizer Tunisie SA, Pfizer Vaccines LLC, Pfizer Venezuela S.A., Pfizer Ventures (US) LLC, Pfizer Ventures LLC, Pfizer Worldwide Services Unlimited Company, Pfizer Zona Franca S.A., Pfizer spol. s r.o., Pharmacia, Pharmacia & Upjohn Company LLC, Pharmacia & Upjohn LLC, Pharmacia Brasil Ltda., Pharmacia Hepar LLC, Pharmacia Inter-American LLC, Pharmacia International B.V., Pharmacia LLC, Pharmacia Limited, PowderMed, Purepac Pharmaceutical Holdings LLC, ReViral, Redvax, Renrall LLC, Rinat Neuroscience, Rinat Neuroscience Corp., Roerig S.A., Searle Laboratorios Lda., Serenex, Servicios P&U S. de R.L. de C.V., Shiley LLC, Sinergis Farma-Produtos Farmaceuticos Lda., Solinor LLC, Sugen LLC, Tabor LLC, Therachon, Trillium Therapeutics, Trillium Therapeutics ULC, Trillium Therapeutics USA LLC, Upjohn Laboratorios Lda., Vicuron Holdings LLC, W-L LLC, Warner Lambert, Warner Lambert del Uruguay S.A., Warner-Lambert Company GmbH, Warner-Lambert Company LLC, Wyeth Ayerst Inc., Wyeth Ayerst S.à r.l., Wyeth Biopharma, Wyeth Farma S.A., Wyeth Holdings LLC, Wyeth Industria Farmaceutica Ltda., Wyeth LLC, Wyeth Lederle S.r.l., Wyeth Pakistan Limited, Wyeth Pharmaceuticals FZ-LLC, Wyeth Pharmaceuticals LLC, Wyeth Subsidiary Illinois Corporation, Wyeth Whitehall Export GmbH, Wyeth-Ayerst (Asia) LLC, Wyeth-Ayerst International LLC, and Wyeth-Ayerst Promotions Limited.
Read More
How can I contact Pfizer?: Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The official website for the company is www.pfizer.com. The biopharmaceutical company can be reached via phone at (212) 733-2323 or via fax at 302-655-5049.

This page (NYSE:PFE) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pfizer (PFE) Stock Forecast, Price & News

Pfizer MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Pfizer (NYSE:PFE) Stock

PFE Stock News Headlines

PFE Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

PFE Stock - Frequently Asked Questions

Overall MarketRank^™